What is Biostat?
Established in 1986, Biostat has carved out a distinct niche in the development of sophisticated computer programs dedicated to statistical power analysis and meta-analysis. The company's trajectory is deeply intertwined with the National Institutes of Health (NIH), having leveraged the Small Business Innovation Research (SBIR) program to fuel its foundational software releases. From the 1988 launch of its initial power analysis tools to the more recent iterations of its Comprehensive Meta Analysis suite, Biostat has maintained a rigorous focus on providing researchers with the precision instruments required for complex data interpretation. Its market position is defined by a legacy of academic and clinical utility, serving as a critical infrastructure provider for the scientific community.
How much funding has Biostat raised?
Biostat has raised a total of $38K across 1 funding round:
Debt
$38K
Debt (2021): $38K with participation from PPP
Key Investors in Biostat
PPP
Public-Private Partnership
What's next for Biostat?
The recent influx of capital is earmarked for the substantial expansion of Biostat's software ecosystem. As the company moves into its next growth phase, the strategic focus will likely center on the deployment of advanced modules for its existing power and meta-analysis platforms. By capitalizing on its long-standing relationship with federal research bodies and its established user base, Biostat is well-positioned to modernize its legacy architecture. The firm aims to integrate contemporary data processing capabilities into its proven statistical frameworks, ensuring that its software remains the gold standard for researchers navigating the complexities of modern meta-analysis and power calculation requirements.
See full Biostat company page
